METHODS FOR CONTROLLING BLOOD-GLUCOSE LEVELS IN INSULIN-REQUIRING SUBJECTS

• US 20120058942A1
• Filed: 09/01/2011
• Published: 03/08/2012
• Est. Priority Date: 09/03/2010
• Status: Abandoned Application

• Current Assignee: John Dupre
• Original Assignee: John Dupre
• Inventors: DUPRE, John
• Application Number:
  US13/223,724
• Publication Number:
  US 20120058942A1
• Time in Patent Office: Days
• US Class Current: 514/6.5
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/4985 Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics

Abstract

The present invention relates to methods of controlling blood glucose levels in subjects receiving an insulin therapy. The methods include administering to the subject receiving an insulin therapy a dipeptidyl peptidase inhibitor and a GLP-1 related peptide. The present invention relates also to the use of such a combination for treating insulin-requiring diabetes mellitus and conditions related thereto.

Claims

1. A method of controlling blood glucose level in a subject receiving an insulin therapy comprising administering to the subject:

(i) a dipeptidyl peptidase inhibitor (DPPI);

and (ii) a glucagon-like petide-1 (GLP-1) related peptide.

2. The method of claim 1 wherein the insulin, DPPI, GLP-1 related peptide and insulin are administered to the subject separately.

3. The method of claim 1 wherein the subject has type 1 or type 2 diabetes mellitus.

4. The method of claim 1 wherein the DPPI is produced by a manufacturer, and the DPPI is administered in the manufacturer'"'"'s recommended dosage.

5. The method of claim 1 wherein the DPPI is administered in a dose range that is equivalent to or less than the therapeutic dose range of DPPI when used individually for controlling blood glucose level in an insulin-requiring subject with diabetes mellitus.

6. The method of claim 1 wherein the DPPI is administered in a dosage that targets between about 40% and about 60% of the inhibition of the level of dipeptidyl peptidase in the subject.

7. The method of claim 1 wherein the DPPI is administered in a dosage of about 100 mg daily or less.

8. The method of claim 1 wherein the GLP-1 related peptide is administered in a dosage which achieves about 50% or more of attainable reduction of blood glucose level after a meal.

9. The method of claim 1 wherein the GLP-1 related peptide is administered in a dosage range that is equivalent to or less than the therapeutic dose range of said GLP-1 related peptide when used alone for controlling blood glucose level in an insulin-requiring subject with diabetes mellitus.

10. The method of claim 1 wherein the dose of GLP-1 related peptide is between about 7 nanograms to about 40 nanograms daily.

11. The method of claim 1 wherein the GLP-1 related peptide is produced by a manufacturer, and the GLP-1 related peptide is administered in the manufacturer'"'"'s recommended dosage.

12. The method of claim 1 wherein the GLP-1 related peptide is selected from GLP-1 7-37 or GLP-1 7-36 amide.

13. The method of claim 1 wherein the insulin dose in the insulin therapy is equivalent to the therapeutic dose range of said insulin when used individually for controlling blood glucose level in an insulin-requiring subject with diabetes mellitus.

14. The method of claim 1 wherein the insulin dose in the insulin therapy is less than the therapeutic dose range of said insulin compound when used alone for controlling blood glucose level in an insulin-requiring subject with diabetes mellitus.

15. A method of optimizing therapeutic efficacy for controlling blood glucose level in a subject receiving an insulin therapy comprising, comprising:

a. establishing a dose of insulin according to insulin therapy guidelines;

b. administering a DPPI to the subject;

c. reducing the dose of insulin administered to the subject; and

d. administering a GLP-related peptide to the subject.

16. The method of claim 15 wherein the subject has type 1 or type 2 diabetes mellitus.

17. The method of claim 15 wherein in said method further comprises monitoring blood glucose level of the subject, and wherein a decrease or an increase in the level of blood glucose indicates a need to adjust the dose of insulin administered to said subject.

18. The method of claim 15 wherein the DPPI is produced by a manufacturer, and the DPPI is administered in the manufacturer'"'"'s recommended dosage.

19. The method of claim 15 wherein the DPPI is administered in a dose range that is equivalent to or less than the therapeutic dose range of DPPI when used individually for controlling blood glucose level in an insulin-requiring subject with diabetes mellitus.

20. The method of claim 15 wherein the DPPI is administered in a dosage that targets between about 40% and about 60% of the inhibition of the level of dipeptidyl peptidase in the subject.

21. The method of claim 15 wherein the DPPI is administered in a dosage of about 100 mg daily or less.

22. The method of claim 15 wherein the GLP-1 related peptide is administered in a dosage which achieves about 50% or more of attainable reduction of blood glucose level after a meal.

23. The method of claim 15 wherein the GLP-1 related peptide is administered in a dosage range that is equivalent to or less than the therapeutic dose range of said GLP-1 related peptide when used individually for controlling blood glucose level in an insulin-requiring subject with diabetes mellitus.

24. The method of claim 15 wherein the GLP-1 related peptide is administered in a dosage of between about 7 nanograms to about 40 nanograms daily.

25. The method of claim 15 wherein the GLP-1 related peptide is produced by a manufacturer, and the GLP-1 related peptide is administered in the manufacturer'"'"'s recommended dosage.

26. The method of claim 15 wherein the GLP-1 related peptide is selected from GLP-1 7-37 or GLP-1 7-36 amide.